FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.

ABSTRACT: Personalized therapy for non‑small cell lung cancer (NSCLC), particularly lung adenocarcinoma, has recently been significantly improved by the discovery of various molecular targets. However, this has not been the case for lung squamous cell carcinoma (SCC). In the present study, we identified the family with sequence similarity 83, member B (FAM83B) as a candidate marker for SCC through a comprehensive gene expression analysis and examined its correlations with various clinicopathological factors. The subjects of this study consisted of 215 patients with NSCLC who underwent complete resection from 2005 to 2011 at the Fukushima Medical University Hospital (Fukushima, Japan). They included 102 patients with adenocarcinoma and 113 with SCC. FAM83B expression was first examined in some of the

SUBMITTER: Okabe N 

PROVIDER: S-EPMC4324586 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature